Display options
Cite
Izumikawa K. Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Front Microbiol. 2016;7:800doi: 10.3389/fmicb.2016.00800.
Izumikawa, K. (2016). Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Frontiers in microbiology, 7800. https://doi.org/10.3389/fmicb.2016.00800
Izumikawa, Koichi. "Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia." Frontiers in microbiology vol. 7 (2016): 800. doi: https://doi.org/10.3389/fmicb.2016.00800
Izumikawa K. Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Front Microbiol. 2016 Jun 01;7:800. doi: 10.3389/fmicb.2016.00800. eCollection 2016. PMID: 27313568; PMCID: PMC4888638.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 Jun 01;7:800. doi: 10.3389/fmicb.2016.00800. eCollection 2016.

Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia.

Frontiers in microbiology

Koichi Izumikawa

Affiliations

  1. Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences Nagasaki, Japan.

PMID: 27313568 PMCID: PMC4888638 DOI: 10.3389/fmicb.2016.00800

Abstract

Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia in children and young adults. The incidence of fulminant M. pneumoniae pneumonia (MPP) is relatively rare despite the high prevalence of M. pneumoniae infection. This literature review highlights the clinical features of fulminant MPP by examining the most recent data in epidemiology, clinical presentation, pathogenesis, and treatment. Fulminant MPP accounts for 0.5-2% of all MPP cases and primarily affects young adults with no underlying disease. Key clinical findings include a cough, fever, and dyspnea along with diffuse abnormal findings in radiological examinations. Levels of inflammatory markers such as white blood cells and C-reactive protein are elevated, as well as levels of lactate dehydrogenase, IL-18, aspartate transaminase, and alanine transaminase. The exact pathogenesis of fulminant MPP remains unclear, but theories include a delayed hypersensitivity reaction to M. pneumoniae and the contribution of delayed antibiotic administration to disease progression. Treatment options involve pairing the appropriate anti-mycoplasma agent with a corticosteroid that will downregulate the hypersensitivity response, and mortality rates are quite low in this treatment group. Further research is necessary to determine the exact pathogenesis of severe and fulminant types of MPP.

Keywords: LDH; Mycoplasma pneumoniae; corticosteroids; fulminant pneumonia; hyperimmune response

References

  1. J Infect Chemother. 2015 Mar;21(3):153-60 - PubMed
  2. Intern Med. 2006;45(7):419-28 - PubMed
  3. Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents - PubMed
  4. Int Immunol. 2001 Jul;13(7):933-40 - PubMed
  5. J Infect Chemother. 2014 Mar;20(3):181-5 - PubMed
  6. J Infect Chemother. 2004 Dec;10(6):359-63 - PubMed
  7. J Med Microbiol. 2007 Dec;56(Pt 12):1625-9 - PubMed
  8. J Med Microbiol. 2005 Apr;54(Pt 4):395-400 - PubMed
  9. Clin Exp Immunol. 1994 Dec;98(3):388-94 - PubMed
  10. Chest. 2002 May;121(5):1493-7 - PubMed
  11. Intern Med. 2002 Mar;41(3):229-32 - PubMed
  12. Intern Med. 2001 Apr;40(4):345-8 - PubMed
  13. Allergy Asthma Immunol Res. 2012 Jan;4(1):55-7 - PubMed
  14. Respir Care. 2015 Oct;60(10):1469-75 - PubMed
  15. West J Med. 1995 Feb;162(2):133-42 - PubMed

Publication Types